Molecular mechanisms of resistance to taxanes and therapeutic implications

Drug Resistance Updates

Volumn 2, Issue 6, 1999, Pages 351-357

  Zunino, Franco ^a   Cassinelli, Giuliana ^a   Polizzi, Donatella ^a   Perego, Paola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CYCLOSPORIN A; DOCETAXEL; GLYCOPROTEIN P; GROWTH FACTOR RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; PACLITAXEL; SURVIVIN; TAXANE DERIVATIVE; TUBULIN;

APOPTOSIS; CANCER RESISTANCE; CELL CYCLE; CROSS RESISTANCE; CYTOSKELETON; DRUG BINDING; GENE OVEREXPRESSION; MICROTUBULE; MITOSIS SPINDLE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0033503104     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0108     Document Type: Article

References (80)

1. Rowinski E. K., Donehower R. C. Paclitaxel (Taxol). Wood A. J.J. Drug therapy. 1995;1004-1012.
2. Horwitz S. B., Cohen D., Rao S., Ringel I., Shen H-J., Yang C-P. H. Taxol: mechanisms of action and resistance. Monogr Natl Cancer Inst. 15:1993;55-61.
3. Dumontet C., Sikic B. I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 17:1999;1061-1070.
4. Jordan M. A., Wendell K., Gardiner S., Derry W. B., Copp H., Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:1996;816-825.
5. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol. 57:1999;1215-1221.
6. Pastan I., Gottesman M. M. Multidrug resistance. Annu Rev Med. 42:1991;277-286.
7. Sparreboom A., Van Asperen J., Mayer U. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 94:1997;2031-2035.
8. Balmaceda C. Advances in brain tumor chemosensitivity. Curr Opin Oncol. 10:1998;194-200.
9. Hosli P., Sappino A. P., de Tribolet N., Dietrich P. Y. Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol. 9:1998;589-600.
10. Van Asperen J., Van Tellingen O., Van der Valk M. A., Rozenhart M., Beijnen J. H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res. 4:1998;2293-2297.
11. Cole S. P. C., Sparks K. E., Fraser K. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:1994;5902-5910.
12. Huang Y., Ibrado A. M., Reed J. C. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 11:1997;253-257.
13. Binaschi M., Supino R., Gambetta R. A. MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int J Cancer. 62:1995;84-89.
14. Vanhoefer U., Cao S., Harstrick A., Seeber S., Rustum Y. M. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol. 8:1997;1221-1228.
15. Royer I., Monsarrat B., Sonnier M., Wright M., Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 56:1996;58-65.
16. Liebmann J. E., Hahn S. M., Cook J. A., Lipschultz C., Mitchell J. B., Kaufman D. C. Glutathione depletion by L-buthionine sulfoximine antagonizes Taxol cytotoxicity. Cancer Res. 53:1993;2066-2070.
17. Nishio K., Saijo N. Cytoskeletons and antimitotic agents developed in Japan. Anti-Cancer Drug Design. 14:1999;133-141.
18. Ohta S., Nishio K., Kubota N. Characterization of a Taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res. 85:1994;290-297.
19. Derry W. B., Wilson L., Khan I. A., Luduena R. F., Jordan M. A. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tybulin isotypes. Biochemistry. 36:1997;3554-3562.
20. Kavallaris M., Burkhart C. A., Horwitz S. B. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer. 80:1999;1020-1025.
21. Giannakakou P., Sackett D. L., Kang Y. K. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 272:1997;17118-17125.
22. Monzó M., Rosell R., Sanchez J. J. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 17:1999;1786-1793.
23. Nishio K., Arioka H., Ishida T. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int J Cancer. 63:1995;688-693.
24. Zhang C. C., Yang J-M., White E., Murphy M., Levine A., Hait W. N. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene. 16:1998;1617-1624.
25. Jordan M. A., Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 10:1998;123-130.
26. Mendelsohn J., Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst. 89:1997;341-343.
27. Yu D., Liu B., Tan M., Li J., Wang S-S., Hung M-C. Overexpression of c- erb B-2/ neu in breast cancer cells confers increased resistance to Taxol viamdr-1 -independent mechanisms. Oncogene. 13:1996;1359-1365.
28. Ueno N. T., Yu D., Hung M. C. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 15:1997;953-960.
29. Brader K. R., Wolf J. K., Hung M. C. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin Cancer Res. 3:1997;2017-2024.
30. Zhang L., Lau Y. K., Xia W., Hortobagyi G. N., Hung M. C. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res. 5:1999;343-353.
31. mdr-1renders breast cancer cells highly resistant to Taxol. Oncogene. 16:1998;2087-2094.
32. Baselga J., Norton L., Albanell J. Recombinant humanized anti HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831.
33. Polizzi D., Pratesi G., Tortoreto M., Supino R., Riva A., Bombardelli E., Zunino F. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res. 59:1999;1036-1040.
34. Ciardiello F., Tortora G. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res. 4:1998;821-828.
35. Ciardiello F., Caputo R., Pomatico G. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer. 1999;in press.
36. Srivastava R. K., Srivastava A. R., Korsmeyer S. J., Nesterova M., Cho-Chung Y. S., Longo D. L. Inolvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol. 18:1998;3509-3517.
37. Yang C-P. H., Galbiati F., Volonté D., Horwitz S. B., Lisanti M. P. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Letters. 439:1998;368-372.
38. Razani B., Rubin C. S., Lisanti M. P. Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J Biol Chem. 274:1999;26353-26360.
39. Zunino F., Perego P., Pilotti S., Pratesi G., Supino R., Arcamone F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol Ther. 76:1997;177-185.
40. Wu G. S., El-Deiry W. S. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin Cancer Res. 2:1996;623-633.
41. Perego P., Giarola M., Righetti S. C. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56:1996;556-562.
42. Vasey P. A., Jones N. A., Jenkins S., Dive C., Brown R. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol. 50:1996;1536-1540.
43. Rudner A. D., Murray A. W. The spindle assembly checkpoint. Curr Opin Cell Biol. 8:1996;773-780.
44. Sorger P. K., Dobles M., Tournebize R., Hyman A. A. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol. 9:1997;807-814.
45. Wahl A. F., Dinaldson K. L., Fairchild C. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med. 2:1996;72-79.
46. Vikhanskaya F., Vignati S., Beccaglia P. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res. 241:1998;96-101.
47. Perego P., Romanelli S., Carenini N. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol. 9:1998;423-430.
48. Gualberto A., Aldape K., Kozakiewicz K., Tlsty T. D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA. 95:1998;5166-5171.
49. Utrera R., Collavin L., Lazarevic D., Delia D., Schneider C. A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. EMBO J. 17:1998;5015-5025.
50. Lavarino C., Delia D., Di Palma S., Zunino F., Pilotti S. P53 in drug resistance in ovarian cancer. Lancet. 349:1997;1556.
51. Blagosklonny M. V., Schulte T., Nguyen P., Trepel J., Neckers L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56:1996;1851-1854.
52. Wang L. G., Liu X. M., Kreis W., Budman D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 44:1999;355-361.
53. Korsmeyer S. J. BCL -2 gene family and the regulation of programmed cell death. Cancer Res. 59:1999;1693-1700.
54. Strobel T., Tai Y-T., Korsmeyer S., Cannistra S. A. BAD partly reverses paclitaxel resistance in human ovarian cancer cells. Oncogene. 17:1998;2419-2427.
55. Srivastava K. K., Mi Q-S., Hardwick J. M., Longo D. L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci USA. 96:1999;3775-3780.
56. Poruchynsky M. S., Wang E. E., Rudin C. M., Blagosklonny M. V., Fojo T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 58:1998;3331-3338.
57. Haldar S., Chintapalli J., Croce C. M. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
58. De Cesare M., Pratesi G., Giusti A., Polizzi D., Zunino F. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts. Br J Cancer. 77:1998;434-439.
59. Li F., Ambrosini G., Chu E. Y. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:1998;580-584.
60. Monzó M., Rosell R., Felip E. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 17:1999;2100-2104.
61. Pucci B., Bellincampi L., Tafani M., Masciullo V., Melino G., Giordano A. Paclitaxel induces apoptosis in saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. Exp Cell Res. 252:1999;134-143.
62. Guenard D., Gueritte-Voegelein F., Dubois J., Potier P. Structure-activity relationships of Taxol and taxotere analogues. Monogr Natl Cancer Inst. 15:1993;79-82.
63. Ojima I., Slater J. C., Michaud E. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem. 39:1996;3889-3896.
64. Distefano M., Scambia G., Ferlini C. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer. 72:1997;844-850.
65. Ojima I., Slater J. C., Kuduk S. D. Syntheses and structure-activity relationships of taxoids derived from 14β-hydroxy-10-deacetylbaccatin III. J. Med. Chem. 40:1997;267-278.
66. Ojima I., Kuduk S. D., Pera P., Veith J. M., Bernacki R. J. Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity. J Med Chem. 40:1997;279-285.
67. Chou T-C., Zhang X-G., Harris C. R. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA. 95:1998;15798-15802.
68. Kowalski R. J., Giannakakou P., Gunasekera S. P., Longley R. E., Day B. W., Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol. 52:1997;613-622.
69. McDaid H., Bhattacharya S. K., Chen K-T. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines. Cancer Chemother Pharmacol. 44:1999;131-137.
70. Ojima I., Chakravarty S., Inoue T. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA. 96:1999;4256-4261.
71. Kobayashi J., Hosoyama H., Wang X-x, Shigemori H., Sudo Y., Tsuruo T. Modulation of multidrug resistance by taxuspine C and other taxoids from japanese yew. Bioorg Med Chem Lett. 8:1998;1555-1558.
72. Milross C. G., Mason K. A., Hunter N. R., Chung W. K., Peters L. J., Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 88:1996;1308-1314.
73. Strobel T., Kraeft S-K., Chen L. B., Cannistra S. A. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res. 58:1998;4776-4781.
74. Lanni J. S., Lowe S. W., Licitra E. J., Liu J. O., Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA. 94:1997;9679-9683.
75. Weller M., Frei K., Groscurth P., Krammer P. H., Yonekawa Y., Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultures human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest. 94:1994;954-964.
76. DiPaola R. S., Rafi M. M., Vyas V. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol. 17:1999;2213-2218.
77. Zhang C. C., Yang J. M., Bash-Babula J. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res. 59:1999;3663-3670.
78. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R. J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res. 57:1997;81-86.
79. De Vincenzo R., Scambia G., Ferlini C. Antiproliferative activity of colchicine analogues on MDR-positive and MDR-negative human cancer cell lines. Anti-Cancer Drug Design. 13:1998;19-33.
80. Shan B., Medina J. C., Santha E. Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA. 96:1999;5686-5691.